Abstract: The invention relates to the fractionation of plasma or serum into at least one albumin fraction and one immunoglobulin fraction by hydrophobic interaction chromatography. The fractionation is carried out using an incremental salt gradient, especially an ammonium sulfate buffer. The invention also relates to preparations obtained by using said method and to their use.

Abstract: An intravenously administrable polyclonal immunoglobulin preparation for the treatment and prophylaxis of bacterial infections containing at least 50% by weight of IgM in terms of the total content of immunoglobulin, exhibiting a low anticomplementary activity, being stable in aqueous solution, and being free of viruses. It can also consist of or also contain a mixture of several monoclonal IgM antibodies. The source material for its manufacture is an immunoglobulin-containing fraction of human, animal, or bacterial provenance. The fraction is treated with an anion exchanger that is eluted with a saline or pH gradient and the eluate is optionally subjected to gel filtration, treated before or after the chromatography with .beta.-propiolactone and PEG 4000, and optionally heated. Treatment with .beta.-propiolactone and ultraviolet light, treatment with solvents and detergents, or pasteurization can also be conducted. Proteins, sugars, or mixtures of amino acids are optionally added to the preparation.

Abstract: Method of manufacturing an intravenously tolerable immunoglobulin-G preparation that is free of aggregates, vasoactive substances and proteolytic enzymes and accordingly appropriate for all types of patients, especially immunosuppressed patients, from a starting material that contains immunoglobulin G but from which the coagulation factors have been removed. The starting material is treated with 0.4 to 1.5% by volume of octanoic acid and then chromatographed, especially on an ion or cation exchanger or hydrophobic matrix.

Abstract: To provide a simple method of preparing biologically active transferrin that can be employed on an industrial scale and that will result in extremely pure and natural transferrin containing no viruses and appropriate for both in-vitro and in-vivo applications, the .gamma.-globulins are precipitated from the fraction containing the transferrin, the precipitant is removed from the residual liquid by ultrafiltration or gel filtration, the liquid is adjusted to a prescribed ionic concentration and protein concentration and (a) treated with .beta.-propiolactone and the solution is subjected to ultraviolet radiation or (b) treated with specific detergents and subjected to ion-exchange chromatography, and the transferrin is concentrated and filtered sterile.

Abstract: A method of producing a virus-safe, storage-stable, and intravenously tolerable immunoglobulin-G preparation. The object is to make the method appropriate for industrial-scale production and economical by means of the enrichment and multistage purification of a plasma that has had the coagulation factors removed from it or of a plasma fraction or serum fraction that contains immunoglobulin G accompanied by treatment with ion exchangers and by ultrafiltration. The precipitant is eliminated, by means of diafiltration or gelfiltration, either from the plasma that has had the coagulation factors removed from it or from the plasma fraction that contains the immunoglobulin G, and the desired ion composition is established. The resulting protein solution is subjected to fractionation over an ion exchanger to separate the immunoglobulin G.

Abstract: Crosslinked hemoglobin preparations of extended shelf life and high oxygen transport capacity can be made by reducing a hemoglobin solution with an oxygen consuming reducing agent down to an oxygen partial pressure of 0 mbar, then adding an effector, crosslinking with a dialdehyde, reducing with a carbonyl-group-specific reducing agent, circulating through an ultrafilter, and stabilizing the product by adding a reducing agent thereto.

Abstract: A method of preparing a solution of lactic or colostric immunoglobulins or both by processing milk or colostrum or both accompanied by precipitation of the caseins, characterized in that milk or colostrum or both are acidified to a pH of 4.0-5.5, subjected to cross-flow filtration in a filtration unit with a mean pore size of 0.1-1.2 .mu.m, and the low-molecular components removed by means of further cross-flow filtration in another filtration unit with a limit of separation of 5 000-80 000 daltons, as well as an agent for treating bacterial and viral infections that consists of a solution obtained by means of said method.

Abstract: To provide a method that allows the preparation, not only from human blood but also from animal blood and in quantities large enough for clinical applications, of highly purified hemoglobin solutions that can be employed for the treatment of humans and that are free of plasma proteins and residual stroma lipids (a) a starting material that contains erythrocytes is pumped over a filter unit that has a pore size between 0.1 and 1.2 .mu.m in circulation against an isotonic washing solution, (b) the product of (a) is hemolyzed and pumped over an ultrafiltration unit that has a permeability of 80,000 to 100,000 D in circulation against water, and (c) the ultrafiltrate obtained in stage (b) is pumped and diafiltered over an ultrafiltration unit that has a permeability of 10,000 to 50,000 D in circulation against water, whereby concentration is conducted before and/or after diafiltration.

Abstract: A process for obtaining hepatitis-safe, sterile, pyrogen- and stroma-free hemoglobin solutions of low potassium content comprising stirring an erythrocyte concentrate with about 1 to 6-times its volume of an about 5 to 15% aqueous solution of a sugar, sugar alcohol or high-molecular-weight colloid, adjusting the pH of the resulting suspension to about 5 to 6.5 with an acid which is physiologically tolerable as salt, allowing the erythrocytes to settle, removing the supernatant from the sediments, adjusting the pH of the sediment to about 7 to 8, homogenizing the sediment, adjusting its hematocrit to about 55 to 60%, treating the mass with a dilute beta-propiolactone solution, hemolyzing the residual solids and forming a suspension thereof, contacting the suspension with a cation exchanger in H.sup.+ form until the pH has decreased to about 5 to 5.5 thereby to precipitate the stroma, separating from the liquid the cation exchanger and precipitated stroma, and adjusting the pH to about 7.2 to 7.6.

Abstract: (2-Amino-4-quinazolinyl)-quanidines of the formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5 and n have the defined meanings, and their physiologically tolerable acid addition salts, process for preparing these compounds, pharmaceutical preparations containing them and their use as medicines.